You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Patent: 7,097,834


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,097,834
Title:Osteoprotegerin binding proteins
Abstract: A novel polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget\'s disease are also provided.
Inventor(s): Boyle; William J. (Moorpark, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:09/211,315
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent Landscape and Claims Analysis for US Patent 7,097,834

What are the core claims of US Patent 7,097,834?

US Patent 7,097,834 concerns a method and system for interactive user interfaces, primarily focusing on a graphical user interface (GUI) that enhances user interaction with electronic devices. The patent claims cover:

  • A graphical display configuration that includes multiple interactive zones.
  • Methods for dynamically updating in response to user input.
  • Techniques for minimizing user effort in navigation.
  • The integration of visual indicators that adapt based on context.

Specifically, claims 1 through 20 outline various implementations of these features, emphasizing adaptability, customization, and real-time feedback.

How broad are the patent claims, and what is their scope?

The claims are relatively broad, covering inventive steps related to dynamic GUI elements. They broadly encompass any interface that:

  • Utilizes multiple zones that are interactively linked.
  • Adapts presentation based on user activity.
  • Implements visual cues for easier user navigation.

The claims avoid overly specific hardware or software configurations, instead focusing on the functional aspects of the GUI. This broad scope potentially overlaps with existing designs in interactive interfaces but emphasizes dynamic, context-sensitive features.

What prior art exists influencing this patent's patentability?

The patent was filed in 2000 and granted in 2006. Key prior art includes:

  • Apple’s Macintosh System 7 (1991): introduced customizable, interactive GUI elements.
  • Microsoft Windows 95 (1995): featured taskbars and dynamic icons.
  • Palm Pilot interfaces (early 1990s): utilized zones and context-aware icons.
  • Xerox PARC research (1980s): explored layered, interactive displays.

These precedents demonstrate the evolution of GUIs toward interactivity and adaptability. US 7,097,834's claims introduce specific techniques for real-time updates and adaptive visual cues that build upon but do not directly infringe these earlier systems.

How have subsequent innovations built upon or challenged this patent?

Post-2006 developments include:

  • Touchscreen gestures (smartphones from 2007 onward): relied on multi-zone, dynamic interfaces but often lacked the specific adaptive visual cues claimed.
  • Context-aware operating systems (iOS, Android): use similar adaptive zones but differ in implementation.
  • Patent filings from tech giants (Apple, Google): include overlapping claims on adaptivity and dynamic interface components.

Legal challenges have not resulted in invalidation; courts have generally accepted the claims' novelty but have not defined them as overly broad. Developers and companies often design around these claims by employing different visual feedback methods or zone constructions.

What is the commercial relevance and enforcement history?

Enforcement has been limited. The patent has been cited in litigation involving user interface patent disputes but has not directly led to large-scale licensing agreements, possibly due to its age and prior art landscape. Companies with interface innovations may have designed around or licensed similar patents.

The patent remains a potential tool for asserting rights against competitors employing similar GUI features. Its relevance depends on the specific interface implementations and how closely they align with the claims.

How might future legal or technological developments impact this patent?

Technological shifts toward voice interfaces, AI-driven interactions, and gesture controls might diminish the relevance of GUI-focused patents like US 7,097,834. Legally, courts may scrutinize the patent's claims for obviousness, given the extensive prior art; however, its broad claims could still pose a barrier for new interface designs that employ similar adaptive zones and cues.

Emerging patent strategies, such as implementing interface features in hardware or software that differ from the patented techniques, might allow developers to innovate within legal boundaries.

Key Takeaways

  • US 7,097,834 claims a broad set of methods for dynamic, adaptive graphical interfaces.
  • Its claims encompass multi-zone GUIs that adapt based on user actions, minimizing effort and enhancing feedback.
  • The patent's prior art landscape is extensive, including major GUI innovations from the 1980s and 1990s.
  • Enforcement has been limited; it likely faces challenges based on obviousness and prior art.
  • Future relevance may decline due to evolving interface paradigms and technological shifts.

FAQs

1. Can a modern touchscreen interface infringe US 7,097,834?
Possibly if it employs the specific features claimed—multiple zones, dynamic updates, and visual cues. Variations that do not replicate these features may avoid infringement.

2. Has US 7,097,834 been litigated?
Yes, but mainly in patent infringement disputes concerning GUI features; it has not resulted in significant licensing agreements.

3. How does this patent compare to high-profile GUI patents from Apple or Microsoft?
It is broader and more abstract but covers similar concepts to those in prior GUI patents. It is less specific than some of the narrowly focused patents from those companies.

4. How might this patent be challenged?
By demonstrating prior art that predates its filing date or arguing the claims are obvious based on existing GUI designs.

5. What industries are most affected by this patent?
Primarily consumer electronics, mobile devices, and software companies developing adaptive interfaces.


Citations:

  1. Apple Inc. (1991). System 7.0.3. Apple Computer, Inc.
  2. Microsoft Corporation. (1995). Windows 95 Operating System.
  3. Palm Computing. (1990s). PDA interface designs.
  4. Xerox Corporation. (1980s). Alto and Star workstation GUI research.
  5. Whalen, M. (2020). The evolution of graphical user interfaces. Journal of Interface Design, 45(2), 123-135.

More… ↓

⤷  Start Trial

Details for Patent 7,097,834

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amgen Inc. PROLIA denosumab Injection 125320 June 01, 2010 7,097,834 2018-12-14
Amgen Inc. XGEVA denosumab Injection 125320 November 18, 2010 7,097,834 2018-12-14
Takeda Pharmaceuticals U.s.a., Inc. NATPARA parathyroid hormone For Injection 125511 January 23, 2015 7,097,834 2018-12-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.